
24/09/2025
NERCHA Welcomes Historic Price Reduction of Lenacapavir PrEP for HIV Prevention ๐
NERCHA welcomes the groundbreaking announcement of a significant price reductions for Lenacapavir PrEP, from USD 28,000 to just USD 40 per year. This historic move marks a turning point in HIV prevention, ensuring that lifesaving innovations are no longer out of reach for the communities that need them most like Eswatini.
Affordable access to long-acting PrEP is a gamechanger in the fight against HIV, particularly for young women and other vulnerable populations disproportionately affected by the HIV epidemic. This breakthrough will greatly accelerate efforts to end AIDS as a public health threat by 2030, aligning with Eswatiniโs commitment to universal health coverage and the global goal of leaving no one behind.
NERCHA commends everyone one who was involved during the negotiations of this deal and accelerating access to generic versions of Lenacapavir. We also recognize the Global Fund and PEPFAR for their commitment to reaching two million people within three years. We are hopeful that a lot of Emaswati will take up this long-acting PrEP to protect themselves from getting infected with HIV.
As NERCHA, we are committed to working with the ministry of health, our partners, communities, and media to ensure that this innovation reaches those who need it most ๐ช